Unknown

Dataset Information

0

ONC201 activates ER stress to inhibit the growth of triple-negative breast cancer cells.


ABSTRACT: ONC201 was previously identified as a first-in-class antitumor agent and small-molecule inducer of the TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) gene that induces apoptosis in cancer cells. ONC201 has a safety profile and is currently in phase II clinical trials for the treatment of various malignancies. In the current study, we examine the effect of ONC201 on triple-negative breast cancer cells (TNBC), a subtype of breast cancer that is sensitive to TRAIL. We find that ONC201 inhibits the growth of TNBC cells including TNBC cells that have developed acquired TRAIL resistance. However, TNBC cells that have developed acquired ONC201 resistance are cross-resistant to TRAIL. Mechanistically, ONC201 triggers an integrated stress response (ISR) involving the activation of the transcription factor ATF4. Knockdown of ATF4 impairs ONC201-induced apoptosis of TNBC cells. Importantly, the activation of ATF4 is compromised in ONC201-resistant TNBC cells. Thus, our results indicate that ONC201 induces an ISR to cause TNBC cell death and suggest that TNBC patients may benefit from ONC201-based therapies.

SUBMITTER: Yuan X 

PROVIDER: S-EPMC5400611 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

ONC201 activates ER stress to inhibit the growth of triple-negative breast cancer cells.

Yuan Xun X   Kho Dhonghyo D   Xu Jing J   Gajan Ambikai A   Wu Kongming K   Wu Gen Sheng GS  

Oncotarget 20170301 13


ONC201 was previously identified as a first-in-class antitumor agent and small-molecule inducer of the TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) gene that induces apoptosis in cancer cells. ONC201 has a safety profile and is currently in phase II clinical trials for the treatment of various malignancies. In the current study, we examine the effect of ONC201 on triple-negative breast cancer cells (TNBC), a subtype of breast cancer that is sensitive to TRAIL. We find that ONC  ...[more]

Similar Datasets

| S-EPMC10496495 | biostudies-literature
| S-EPMC9283343 | biostudies-literature
| S-EPMC5564301 | biostudies-literature
| S-EPMC8110995 | biostudies-literature
| S-EPMC6941316 | biostudies-literature
| S-EPMC8699375 | biostudies-literature
| S-EPMC4348963 | biostudies-literature
| S-EPMC6289793 | biostudies-literature
| S-EPMC6886242 | biostudies-literature
| S-EPMC6881519 | biostudies-literature